Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Triple Negative Breast Neoplasms × Albumin-Bound Paclitaxel × Clear all

Phase

Phase 2 24 Phase 3 6 Phase 1 3 Phase 1/2 2 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 2 Breast Neoplasms 2 Biliary Tract Neoplasms 2 Triple Negative Breast Neoplasms 1 Neoplasms 1 Cholangiocarcinoma 1

Interventions

Carboplatin 6 Gemcitabine 4 130-nm albumin-bound paclitaxel 3 Paclitaxel 2 olaparib 1 eryaspase 1 camrelizumab 1 Erythrocyte Count 1 Epirubicin 1 Doxorubicin 1 Docetaxel 1 Cyclophosphamide 1 Cisplatin 1 Capecitabine 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01881230 2019-02-21

tnAcity

Celgene

Phase 2/3 Completed

191 enrolled 22 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡